PARIS, November 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) for use in studying mouse models of human disease. These SpliceArray(TM) products help our clients accelerate and refine their therapeutic target discovery and validation efforts. Using our high resolution expression profiling analysis, we identify novel transcripts coding for new protein variants that may be involved in various genetic disorders such as oncology, central nervous system, or immune system disorders. This mouse SpliceArray(TM) products represent the achievement of more two years of work by our R&D team after the launch of the Human genome SpliceArray(TM) in 2007 and the rat genome SpliceArray(TM) earlier this year.
"ExonHit has added another important species to its target discovery services portfolio. This addition will expand our ability to service scientists who use the mouse as a disease model, as well as our own discovery programs for novel therapeutic targets and biomarkers," said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics.
"These new Mouse SpliceArray(TM) products will further accelerate the understanding of mechanism of action and ultimately boost the discovery and validation of new therapeutics for ExonHit, using the Mouse as a disease model system, especially in the fields of oncology and CNS disease; this unique approach enabling to save months of preclinical development time," stated Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics.
About ExonHit Therapeutics
ExonHit Therapeutics is the world's leader in the analysis of alternative
RNA splicing, a process which when deregulated plays a key role i
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved